La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Quince Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG Quince Therapeutics' est Dirk Thye, nommé en May2022, a un mandat de 2.25 ans. La rémunération annuelle totale est $ 1.33M, composée du salaire de 41.3% et des bonus 58.7%, y compris les actions et options de la société. détient directement 1.6% des actions de la société, d'une valeur de $ 378.83K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.3 ans et 5.4 ans.

Informations clés

Dirk Thye

Directeur général

US$1.3m

Rémunération totale

Pourcentage du salaire du PDG	41.3%
Durée du mandat du directeur général	2.4yrs
Propriété du PDG	2.0%
Durée moyenne d'occupation des postes de direction	1.4yrs
Durée moyenne du mandat des membres du conseil d'administration	5.6yrs

Mises à jour récentes de la gestion

Recent updates

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 20

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Mar 10

Analyse de la rémunération des PDG

Comment la rémunération de Dirk Thye a-t-elle évolué par rapport aux bénéfices de Quince Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$1m	US$550k	-US$31m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$5m	US$317k	-US$52m

Rémunération vs marché: La rémunération totale de Dirk ($USD 1.33M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Dirk a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Dirk Thye (54 yo)

2.4yrs

Titularisation

US$1,330,500

Compensation

Dr. Dirk Thye, M.D., served as Chief Executive Officer, President and Director at Novosteo Inc. He has been Director at Kainomyx, Inc. Dr. Thye serves as Chief Medical Officer of Quince Therapeutics, Inc....

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Dirk Thye	CEO, Chief Medical Officer & Director	2.4yrs	US$1.33m	1.95% $ 633.0k
Charles Ryan	President	1.1yrs	US$1.11m	0.28% $ 91.8k
Brendan Hannah	Chief Business Officer	1.6yrs	US$847.50k	0.69% $ 222.4k
Giovanni Mambrini	Chief Technology Officer	less than a year	pas de données	pas de données
Guenter Janhofer	Chief Scientific Officer	less than a year	pas de données	0.035% $ 11.3k
Stacy Roughan	Vice President of Corporate Communications & Investor Relations	3.8yrs	pas de données	pas de données
Mary Sillivos	Vice President of Human Resources	4.8yrs	pas de données	pas de données
Stewart Low	Head of Discovery	2.4yrs	pas de données	pas de données
Thomas Sabia	Chief Commercial Officer	less than a year	pas de données	pas de données
Pamela Williamson	Head of Regulatory Affairs	1.3yrs	pas de données	pas de données

1.4yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de QNCX n'est pas considérée comme expérimentée (ancienneté moyenne 1.3 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Dirk Thye	CEO, Chief Medical Officer & Director	2.4yrs	US$1.33m	1.95% $ 633.0k
Una Ryan	Lead Independent Director	5.8yrs	US$98.56k	0.0066% $ 2.2k
Ilan Zipkin	Member of Scientific Advisory Board	no data	US$44.84k	pas de données
Jeffrey Cummings	Member of Clinical Advisory Board	5.3yrs	pas de données	pas de données
Martin Farlow	Member of Clinical Advisory Board	no data	pas de données	pas de données
David Lamond	Independent Chairman of the board	8.8yrs	US$106.06k	10.13% $ 3.3m
Christopher Senner	Independent Director	5.6yrs	US$87.56k	0% $ 0
Margaret McLoughlin	Independent Director	8.8yrs	US$82.06k	0.018% $ 6.0k
Mark Brody	Member of Clinical Advisory Board	no data	pas de données	pas de données
David Munoz	Member of Clinical Advisory Board	no data	pas de données	pas de données
Mark Ryder	Member of Clinical Advisory Board	no data	pas de données	pas de données
Mauro Magnani	Chairman of Scientific Advisory Board	less than a year	pas de données	pas de données

5.6yrs

Durée moyenne de l'emploi

58.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de QNCX sont considérés comme expérimentés (ancienneté moyenne 5.4 ans).

Quince Therapeutics Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

CEO, Chief Medical Officer & Director recently bought US$107k worth of stock

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Recent updates

CEO, Chief Medical Officer & Director recently bought US$107k worth of stock

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics, Inc. Announces the Online Publication of Data in the Lancet Neurology from Its Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Insufficient new directors

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Appoints Luca Benatti as Director

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million.

Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex

Quince Therapeutics Appoints Charles S. Ryan as President

Independent Chairman of the board recently bought US$108k worth of stock

Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023

CEO, President & Director recently bought US$99k worth of stock

New minor risk - Share price stability

Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million.

Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million.

Price target increased by 56% to US$12.00

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Insufficient new directors

Insufficient new directors

Quince Therapeutics, Inc. Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Price target increased to US$8.38

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme to change name and ticker symbol next month

Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 2000 Dynamic Index

Cortexyme, Inc. Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. Appoints June Bray to its Board of Directors

Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer

Cortexyme, Inc. (NasdaqGS:CRTX) acquired Novosteo Inc. from David Lamond and others for $19.8 million.

Dr. Dirk Thye and Philip Low to Join Cortexyme Board

Price target decreased to US$7.60

Cortexyme, Inc. Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of Its Phase 1 Clinical Trial of Cor588

Price target decreased to US$7.60

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Cortexyme, Inc. Announces Executives Changes

Cortexyme, Inc. Receives Letter from the U.S. Food and Drug Administration, Placing Full Clinical Hold on Atuzaginstat’s (COR388) Investigational New Drug Application

Price target increased to US$44.00

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

COO, CFO & Treasurer exercised options to buy US$387k worth of stock.

Cortexyme: A Challenging Path Forward

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

COO, CFO & Treasurer exercised options and sold US$217k worth of stock

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

Cortexyme: Alzheimer's Readout In November A Binary Event

Cortexyme, Inc. Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

Price target increased to US$97.71

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Price target increased to US$89.00

Price target increased to US$78.29

Cortexyme, Inc. Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021

COO, CFO & Treasurer exercised options and sold US$1.0m worth of stock

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 3000E Value Index

Independent Director Kevin Young has left the company

Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting

Cortexyme EPS beats by $0.02